These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 21045136)
21. Overcoming kinase resistance in chronic myeloid leukemia. Lee F; Fandi A; Voi M Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881 [TBL] [Abstract][Full Text] [Related]
22. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Branford S; Rudzki Z; Walsh S; Grigg A; Arthur C; Taylor K; Herrmann R; Lynch KP; Hughes TP Blood; 2002 May; 99(9):3472-5. PubMed ID: 11964322 [TBL] [Abstract][Full Text] [Related]
23. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140 [TBL] [Abstract][Full Text] [Related]
24. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961 [TBL] [Abstract][Full Text] [Related]
25. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053 [No Abstract] [Full Text] [Related]
26. Resistance in the land of molecular cancer therapeutics. Shannon KM Cancer Cell; 2002 Aug; 2(2):99-102. PubMed ID: 12204529 [TBL] [Abstract][Full Text] [Related]
32. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516 [TBL] [Abstract][Full Text] [Related]
33. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression. Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078 [TBL] [Abstract][Full Text] [Related]
34. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059 [TBL] [Abstract][Full Text] [Related]
35. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532 [TBL] [Abstract][Full Text] [Related]
36. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Branford S; Rudzki Z; Parkinson I; Grigg A; Taylor K; Seymour JF; Durrant S; Browett P; Schwarer AP; Arthur C; Catalano J; Leahy MF; Filshie R; Bradstock K; Herrmann R; Joske D; Lynch K; Hughes T Blood; 2004 Nov; 104(9):2926-32. PubMed ID: 15256429 [TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784 [TBL] [Abstract][Full Text] [Related]
38. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. Chien JH; Tang JL; Chen RL; Li CC; Lee CP Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297 [TBL] [Abstract][Full Text] [Related]
39. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016 [TBL] [Abstract][Full Text] [Related]
40. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]